Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

DER 45 EV · DER 45

Other · developed by Sol-Gel Technologies

Phase 2 Most advanced trial (none active)
SLGL Developer
1 Registered trials

What is DER 45 EV?

DER 45 EV is a topically applied agent studied for rosacea of the face, applied to the skin over 12 weeks.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DER 45
Drug type
Other
Therapy area
Dermatology
Developer
Sol-Gel Technologies, Ltd. (SLGL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00940992 Phase 2 Rosacea Completed SLGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rosacea

More from Sol-Gel Technologies

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SLGL page.

Follow SLGL, the company behind DER 45 EV

See SLGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SLGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.